Market Overview

UPDATE: Piper Jaffray Cuts PT to $32 on Theravance Following New Convertible Offering

Related THRX
Morning Market Losers
18 Biotech Stocks These Wall Street Analysts Are Tracking

Piper Jaffray reiterated its Overweight rating on Theravance (NASDAQ: THRX) and lowered the price target from $35.00 to $32.00.

Piper Jaffray commented, “We are reiterating our OW rating on THRX shares, but lowering our PT to $32 from $35 following a $287.5mn convertible offering. We believe current valuation assumes less than 50/50 chance of Breo getting regulatory approval by its May 12, 2013 PDUFA date and assumes additional Phase III trials are required prior to approval of Anoro (LAMA/LABA). We expect the Breo FDA panel on March 7, 2013 to pave the way for a 2013 launch and support upside to shares closer to our price target.”

Theravance closed at $21.27 on Friday.

Latest Ratings for THRX

May 2015Cowen & CompanyDowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (THRX)

Around the Web, We're Loving...